Dapoxetine Delay: J&J’s Premature Ejaculation Drug "Not Approvable" At FDA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA has deemed Johnson & Johnson’s premature ejaculation drug dapoxetine "not approvable," subsidiary Alza announced Oct. 26.